Patrick J McLaren1, Nathan W Bronson2, Kyle D Hart1, Gina M Vaccaro3, Ken M Gatter4, Charles R Thomas5, John G Hunter1, James P Dolan6. 1. Division of Gastrointestinal Surgery, Department of Surgery, Oregon Health and Science University, 3181 Sam Jackson Park Rd, Portland, OR, 97239, USA. 2. Department of General Surgery, Kaiser Permanente, Sunnyside, Portland, OR, USA. 3. Division of Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR, USA. 4. Department of Pathology, Oregon Health and Science University, Portland, OR, USA. 5. Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, USA. 6. Division of Gastrointestinal Surgery, Department of Surgery, Oregon Health and Science University, 3181 Sam Jackson Park Rd, Portland, OR, 97239, USA. dolanj@ohsu.edu.
Abstract
INTRODUCTION: We hypothesized that serum neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may predict pathologic complete response to neoadjuvant chemoradiotherapy in esophageal cancer patients. The ability to predict favorable treatment response to therapy may aid in determining optimal treatment regimens. MATERIALS AND METHODS: A retrospective review of a prospective esophageal disease registry was conducted. Neutrophil-to-lymphocyte ratio was defined as the pre-chemoradiotherapy serum neutrophil count divided by lymphocyte count. Platelet-to-lymphocyte ratio was similarly defined. Logistic regression was applied to analyze these ratios and their effect on pathologic complete response. A Cox proportional-hazards model was used to analyze survival. RESULTS: Sixty patients were included. Elevated neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio were both negative predictors of pathologic complete response (odds ratio: 0.62; 95% confidence interval: 0.37-0.89, P = 0.037 and odds ratio: 0.91; 95% confidence interval: 0.82-0.98, P = 0.028, respectively). Only platelet-to-lymphocyte ratio was predictive of decreased overall survival (hazard ratio: 1.05, 95% confidence interval: 0.94-1.16, P = 0.40). CONCLUSION: Elevated neutrophil and platelet-to-lymphocyte ratios were significant predictors of a poor treatment response to neoadjuvant therapy. Only elevated platelet-to-lymphocyte ratio was predictive of worse overall survival. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may offer a simple serum test to assess the likelihood of a pathologic complete response after neoadjuvant therapy in esophageal cancer.
INTRODUCTION: We hypothesized that serum neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may predict pathologic complete response to neoadjuvant chemoradiotherapy in esophageal cancerpatients. The ability to predict favorable treatment response to therapy may aid in determining optimal treatment regimens. MATERIALS AND METHODS: A retrospective review of a prospective esophageal disease registry was conducted. Neutrophil-to-lymphocyte ratio was defined as the pre-chemoradiotherapy serum neutrophil count divided by lymphocyte count. Platelet-to-lymphocyte ratio was similarly defined. Logistic regression was applied to analyze these ratios and their effect on pathologic complete response. A Cox proportional-hazards model was used to analyze survival. RESULTS: Sixty patients were included. Elevated neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio were both negative predictors of pathologic complete response (odds ratio: 0.62; 95% confidence interval: 0.37-0.89, P = 0.037 and odds ratio: 0.91; 95% confidence interval: 0.82-0.98, P = 0.028, respectively). Only platelet-to-lymphocyte ratio was predictive of decreased overall survival (hazard ratio: 1.05, 95% confidence interval: 0.94-1.16, P = 0.40). CONCLUSION: Elevated neutrophil and platelet-to-lymphocyte ratios were significant predictors of a poor treatment response to neoadjuvant therapy. Only elevated platelet-to-lymphocyte ratio was predictive of worse overall survival. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may offer a simple serum test to assess the likelihood of a pathologic complete response after neoadjuvant therapy in esophageal cancer.
Authors: Guillaume Piessen; Mathieu Messager; Xavier Mirabel; Nicolas Briez; William B Robb; Antoine Adenis; Christophe Mariette Journal: Ann Surg Date: 2013-11 Impact factor: 12.969
Authors: Daniela Poppe; Imke Tiede; Gerhard Fritz; Christoph Becker; Brigitte Bartsch; Stefan Wirtz; Dennis Strand; Shinya Tanaka; Peter R Galle; Xosé R Bustelo; Markus F Neurath Journal: J Immunol Date: 2006-01-01 Impact factor: 5.422
Authors: Birat Dhungel; Brian S Diggs; John G Hunter; Brett C Sheppard; John T Vetto; James P Dolan Journal: J Gastrointest Surg Date: 2010-09-08 Impact factor: 3.452
Authors: Arianna Barbetta; Tamar B Nobel; Smita Sihag; Meier Hsu; Kay See Tan; Manjit S Bains; James M Isbell; Yelena Y Janjigian; Abraham J Wu; Matthew J Bott; David R Jones; Daniela Molena Journal: Ann Thorac Surg Date: 2018-05-05 Impact factor: 4.330